Lv1
40 积分 2023-02-21 加入
实验室自建肿瘤全景变异检测性能确认中国专家共识（2024年版）
2个月前
已完结
Early stage NSCLC - challenges to implementing ctDNA-based screening and MRD detection
8个月前
已完结
Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial
8个月前
已完结
Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA
9个月前
已完结
Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial
9个月前
已完结
Unintrusive multi-cancer detection by circulating cell-free DNA methylation sequencing (THUNDER): development and independent validation studies
1年前
已完结
Molecular classification of hormone receptor-positive HER2-negative breast cancer
1年前
已完结
Immunotherapy combined with chemotherapy has been shown to be efficacious as treatment for advanced non-squamous non-small-cell lung cancer (NSCLC) without targetable genetic aberrations; however, there is scarce evidence of the effectiveness of the combinations in the Asian population. We evaluated camrelizumab plus chemotherapy against non-squamous NSCLC in China
1年前
已完结
Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer: a multicentre, open-label, randomised phase 3 study
1年前
已完结
Classification and characterization of microsatellite instability across 18 cancer types
1年前
已完结
皖公网安备34019202002308
